Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.

953results about How to "Inhibit progress" patented technology

Filter

Efficacy Topic

Property

Owner

Technical Advancement

Application Domain

Technology Topic

Technology Field Word

Patent Country/Region

Patent Type

Patent Status

Application Year

Inventor

Method, apparatus, and surgical technique for autonomic neuromodulation for the treatment of disease

InactiveUS20060167498A1Reduce or prevent conditionReducing and preventing symptomSpinal electrodesSurgical needlesSplanchnic nervesDisease

The present invention teaches a method and apparatus for physiological modulation, including neural and gastrointestinal modulation, for the purposes of treating several disorders, including obesity, depression, epilepsy, and diabetes. This includes chronically implanted neural and neuromuscular modulators, used to modulate the afferent neurons of the sympathetic nervous system to induce satiety. Furthermore, this includes neuromuscular stimulation of the stomach to effect baseline and intermittent smooth muscle contraction to increase gastric intraluminal pressure, which induces satiety, and stimulate sympathetic afferent fibers, including those in the sympathetic trunk, splanchnic nerves, and greater curvature of the stomach, to augment the perception of satiety.

Method, apparatus, and surgical technique for autonomic neuromodulation for the treatment of disease

View all

Owner:DILORENZO BIOMEDICAL

FcgammaRIIB-specific antibodies and methods of use thereof

ActiveUS20040185045A1Strong therapeutic activityEnhancing antibody-mediated effector functionSenses disorderAntipyreticTherapeutic antibodyTreatment effect

The present invention relates to antibodies or fragments thereof that specifically bind FcgammaRIIB, particularly human FcgammaRIIB, with greater affinity than said antibodies or fragments thereof bind FcgammaRIIA, particularly human FcgammaRIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.

FcgammaRIIB-specific antibodies and methods of use thereof

View all

Owner:MACROGENICS INC

Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes

ActiveUS8252592B2Increase self-toleranceIncrease and reduces immune responseFused cellsFermentationRegulatory T cellLymphocyte

The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen-recognizing receptor and a co-stimulatory ligand and methods of use therefore for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.

Owner:MEMORIAL SLOAN KETTERING CANCER CENT

External wearable light therapy treatment systems

InactiveUS20070129776A1Reinforced jointsImprove abilitiesDiagnosticsSurgeryLight therapyLight energy

A light therapy system provides for self-alignment or positioning with respect to a joint of a subject. The light therapy system can provide light therapy to a body part of a subject. The therapy system has a main body configured to be placed adjacent a target site and an activatable light emitting system is coupled to the main body. The light emitting system is capable of delivering a therapeutic amount of light energy to the target site when the main body is placed adjacent the target site.

External wearable light therapy treatment systems

View all

Owner:LIGHT SCI ONCOLOGY

2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones

InactiveUS6936612B2Inhibit progressUtility as antiinfective agentsBiocideAntimycoticsPyridineCyclin

The present invention provides substituted 2-aminopyridines useful in treating cell proliferative disorders. The novel compounds of the present invention are potent inhibitors of cyclin-dependent kinases 4 (cdk4)

2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones

View all

Owner:WARNER LAMBERT CO LLC

Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions

ActiveUS20060083720A1Inhibit progressBiocideArtificial cell constructsProgenitorDisease cause

Adipose derived regenerative cells are used to treat patients, including patients with cardiovascular conditions, diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells, e.g., stem and / or progenitor cells, obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, adipose derived regenerative cells are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic cardiovascular benefit.

Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions

View all

Owner:LOREM VASCULAR PTE LTD

Method and apparatus for conformal electrodes for autonomic neuromodulation for the treatment of obesity and other conditions

InactiveUS20090118780A1Reduce or prevent conditionReducing and preventing symptomSpinal electrodesHead electrodesAfferent NeuronsAutonomic Denervation

The present invention teaches a method and apparatus for user control and operation of physiological modulation, including neural and gastrointestinal modulation, for the purposes of treating several disorders, including obesity, metabolic disease, and other conditions. This includes programming of neuromodulatory signal for the modulation of autonomic neural and neuromuscular modulators, used to modulate tissues, including the afferent neurons of the sympathetic nervous system to induce satiety and efferent neurons to modulate metabolism. The apparatus and methods include a conformal neuromodulator array which facilitates minimally invasive placement of neuromodulators in communication with target tissues.

Method and apparatus for conformal electrodes for autonomic neuromodulation for the treatment of obesity and other conditions

View all

Owner:DILORENZO DANIEL JOHN

Systems for Sustained Intraocular Delivery of Low Solubility Compounds from a Port Delivery System Implant

ActiveUS20140276482A1Improve solubilityHigh concentrationOrganic active ingredientsPharmaceutical delivery mechanismSolubilityBiomedical engineering

Therapeutic agent delivery formulations for the sustained release of therapeutic agents from a Port Delivery System (PDS) implant is described in this application.

Systems for Sustained Intraocular Delivery of Low Solubility Compounds from a Port Delivery System Implant

View all

Owner:FORSIGHT VISION5 INC

Methods of treating metabolic syndrome using dopamine receptor agonists

InactiveUS20080200453A1Relieve symptomsEffective treatmentBiocideMetabolism disorderDiseaseVascular disease

The present invention is directed to a method of simultaneously treating hypertension, hypertriglyceridemia, a pro-inflammatory state, a pro-coagulative state, and insulin resistance (with or without treating obesity or endothelial dysfunction), associated with or independent from Metabolic Syndrome, as well as vascular disease such as cardiovascular, cerebrovascular, or peripheral vascular disease comprising the step of administering to a patient suffering from such disorders a therapeutically effective amount of a central acting dopamine agonist. In one embodiment, the central acting dopamine agonist is bromocriptine, optionally combined with a pharmaceutically acceptable carrier.

Methods of treating metabolic syndrome using dopamine receptor agonists

View all

Owner:VEROSCI

Contact lens comprising non-coaxial lenslets for preventing and/or slowing myopia progression

ActiveUS20160377884A1Good distance vision correctionCorrection acuitySpectales/gogglesOptical partsPupilRetina

Contact lenses incorporating an array of non-coaxial lenslets with add power that create non-coaxial myopic defocus within the optic zone of the lens may be utilized to prevent and / or slow myopia progression. The positive, non-coaxial lenslets cover about twenty to eighty percent of the central pupil area to deliver positive foci of light in front of the retina to slow the rate of myopia progression.

Contact lens comprising non-coaxial lenslets for preventing and/or slowing myopia progression

View all

Owner:JOHNSON & JOHNSON VISION CARE INC

Method and apparatus for programming of autonomic neuromodulation for the treatment of obesity

InactiveUS20090187230A1Reduce or prevent conditionReducing and preventing symptomSensorsDigestive electrodesAfferent NeuronsDisease

The present invention teaches methods and apparatus for user control and operation of physiological modulation, including neural and gastrointestinal modulation, for the purposes of treating several disorders, including obesity. This includes programming of neuromodulatory signal for the modulation of autonomic neural and neuromuscular modulators, used to modulate tissues, including the afferent neurons of the sympathetic nervous system to induce satiety and efferent neurons to modulate metabolism.

Method and apparatus for programming of autonomic neuromodulation for the treatment of obesity

View all

Owner:DILORENZO DANIEL J

Compounds and methods for treatment of cancer

ActiveUS20070004627A1Reduce tumor volumeInhibit tumor growthBiocidePeptide/protein ingredientsLymphatic SpreadImproved survival

The invention relates to methods and compounds for treating or preventing cancer. Methods for treating or preventing cancer, for inhibiting tumor growth, reducing tumor volume, inhibiting tumor progression, inhibiting metastasis, and improving survival are provided herein.

Compounds and methods for treatment of cancer

View all

Owner:FIBROGEN INC

Gsk-3betainhibitor

InactiveUS20100069381A1Superior GSK-3 specific inhibitory activityImprove solubilityAntibacterial agentsBiocideDiseaseDitazole

For the purpose of providing a GSK-3β inhibitor containing an oxadiazole compound or a salt thereof or a prodrug thereof useful as an agent for the prophylaxis or treatment of a GSK-3β-related pathology or disease, the present invention provides a GSK-3β inhibitor containing a compound represented by the formula (I):wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof.

View all

Owner:TAKEDA PHARMA CO LTD

Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes

ActiveUS20100178276A1Prevent metastasisPrevent occurrence and recurrenceAntibacterial agentsAntimycoticsT cellT lymphocyte

View all

Owner:MEMORIAL SLOAN KETTERING CANCER CENT

Influenza virus vaccines and uses thereof

ActiveUS20100297174A1Reduce severityImprove survivalSsRNA viruses negative-sensePeptide/protein ingredientsHemagglutininInfluenza virus vaccine

Provided herein are influenza hemagglutinin stem domain polypeptides, compositions comprising the same, vaccines comprising the same and methods of their use.

Influenza virus vaccines and uses thereof

View all

Owner:MT SINAI SCHOOL OF MEDICINE

Antibody to cytokine response gene 2(CR2) polypeptide

InactiveUS6057427AHigh incidenceEliminate the effects ofCytokine-induced proteinsPeptide/protein ingredientsAntibody fragmentsAmino acid

PCT No. PCT / US96 / 08992 Sec. 371 Date Jun. 5, 1996 Sec. 102(e) Date Jun. 5, 1996 PCT Filed Jun. 5, 1996Disclosed are an isolated antibody or antibody fragment that selectively binds a polypeptide encoded by Cytokine Response gene 2 (CR2), and in particular, selectively binds to a first polypeptide having the sequence of residues 1-60 of SEQ. ID No: 4. Also disclosed is a composition containing the antibody or antibody fragment and a diluent or carrier. Also disclosed are methods, using the present antibody or antibody fragment, of isolating or purifying a peptide comprising an amino acid sequence of residues 1-60 of SEQ. ID No: 4 or an antibody binding fragment thereof that is at least 10 to 30 amino acids long, or a fusion protein comprising any of these.

Owner:TRUSTEES OF DARTMOUTH COLLEGE THE

Complement Binding Aptamers and Anti-C5 Agents Useful in the Treatment of Ocular Disorders

InactiveUS20090269356A1Lower Level RequirementsImprove acuityBiocideSenses disorderDiseaseEye disease

Methods of treating complement-mediated ocular disorders by administering agents that inhibit a subject's complement component in an amount sufficient to treat the ocular disorder wherein, in a selected embodiment, said agent is an anti-complement aptamer that, in a preferred embodiment, is an anti-C5 aptamer.

Complement Binding Aptamers and Anti-C5 Agents Useful in the Treatment of Ocular Disorders

View all

Owner:ARCHEMIX CORP

Immunoglobulin variants and uses thereof

InactiveUS20100098730A1Preventing occurrencePrevent recurrenceImmunoglobulins against growth factorsAntibody ingredientsHalf-lifeIn vivo

Variant immunoglobulins with one or more amino acid modifications in the Fc region that have increased in vivo half-lives, and methods of using the same are provided.

Immunoglobulin variants and uses thereof

View all

Owner:F HOFFMANN LA ROCHE & CO AG

Sustained release implants and methods for subretinal delivery of bioactive agents to treat or prevent retinal disease

InactiveUS20060257451A1Inhibit progressQuantity maximizationSenses disorderEye implantsChoroid membraneOphthalmology

The invention relates to sustained release implants and to methods for treating eyes, particularly the eyes of mammals having eye disorders or diseases. By using the implants and methods described herein, the delivery of the one or more bioactive agents can be localized at a desired treatment site, particularly the choroid and the retina.

Sustained release implants and methods for subretinal delivery of bioactive agents to treat or prevent retinal disease

View all

Owner:SURMODICS INC

Effective generation of tumor-targeted t cells derived from pluripotent stem cells

ActiveUS20160009813A1Improve survivalGood antitumor activityAntibody mimetics/scaffoldsMammal material medical ingredientsAntigenPluripotential stem cell

The present invention relates to the field of adoptive immunotherapy. The invention provides methods for generating phenotypically defined, functional, and / or expandable T cells from pluripotent stem cells engineered through safe genetic modifications. The engineered cells may provide one or more of: 1) targeting a specific predetermined antigen expressed on the cell surface of a target cell in an HLA independent manner, 2) enhanced survival and functional potential 3) “off-the-shelf” T cells for administration to multiple recipients, eventually across immunogenic barriers, and / or 4) cytotoxic potential and anti-tumor activity.

Effective generation of tumor-targeted t cells derived from pluripotent stem cells

View all

Owner:MEMORIAL SLOAN KETTERING CANCER CENT

Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d] pryimidin-7-ones

InactiveUS7781583B2Inhibit progressUtility as antiinfective agentsOrganic chemistryAntineoplastic agentsStereochemistry

The present invention provides methods of preparing substituted 2-(pyridin-2-ylamino)-pirido[2,3-d]pyrimidin-7-ones (formula 1),useful in treating cell proliferative disorders, or a pharmaceutically acceptable salt thereof.

Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d] pryimidin-7-ones

View all

Owner:PFIZER INC

Artificial cornea

InactiveUS6391055B1Easy to carryReduce stimulationEye implantsAqueous humorOptical transparency

An artificial cornea comprising an optical element made of an optically transparent material, having a front surface and a posterior surface, and a skirt provided so as to support with surrounding at least a part of the optical element, characterized in that the skirt is provided with a flange on its side facing the interior of eyes during implantation of the artificial cornea and the flange radially protrudes outward from the skirt. The artificial cornea can be well compatible with ocular tissue, prevent leakage of intraocular aqueous humor and intraocular invasion of bacteria, reduce stimulation on palpebral conjunctiva and further, inhibit progression of the down growth, and which has no possibility of reduction in transparency of the optical element due to the down growth as well as detachment and extrusion from the implanted state.

View all

Owner:MENICON CO LTD

Treatment of disc degenerative disease and compositions for same

ActiveUS20100008992A1Improve angiogenesisInhibit progressBiocidePowder deliveryCell typeLBP - low back pain

Methods and compositions for treating or ameliorating lower back pain by administering an effective amount of one or more cell types, alone, and / or in combination with a matrix, and / or in combination with growth factors, in order to stimulate lumbar angiogenesis, decrease inflammation, and stimulating regeneration.

Owner:STEMSPINE INC

Human regulatory molecules

InactiveUS6132973AIncrease ratingsLong half-lifeFungiBacteriaAgonistPolynucleotide

The invention provides human regulatory molecules and polynucleotides (collectively designated HRM) which identify and encode them. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention further provides methods for diagnosing, preventing, and treating disorders associated with expression of human regulatory molecules.

Owner:INCYTE PHARMA INC

Compositions and methods for modulating NH2-terminal Jun Kinase activity

InactiveUS7232897B2Reduce expressionIncrease insulin sensitivityOrganic active ingredientsBiocideDiabetes mellitusKinase

Disclosed herein are compositions and methods used to modulate a NH2-terminal Jun Kinase activity. These compositions and methods can be employed to regulate metabolic disorders associated with, for example, insulin such as diabetes. The reduction in NH2-terminal Jun Kinase activity can lead to the reduction in weight and improve insulin sensitivity.

Compositions and methods for modulating NH2-terminal Jun Kinase activity

View all

Owner:HARVARD UNIV

Extracellular adhesive proteins

InactiveUS20010010913A1High viscosityHighly concentrated solutionAntibacterial agentsFungiExtracellularAgonist

The invention provides human extracellular adhesive proteins (EXADH) and polynucleotides which identify and encode EXADH. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of EXADH.

View all

Owner:INCYTE PHARMA INC

Methods, systems, and kits for plaque stabilization

InactiveUS20030069525A1Increasing the thicknessHigh strengthUltrasound therapySurgeryBlood vessel wallsGrowth Factor Gene

Atherosclerotic plaque and blood vessels may be stabilized by directing vibrational energy, typically ultrasonic energy, into the adjacent blood vessel wall. Application of the vibrational energy, optionally in combination with growth factors, growth factor genes, or other substances which enhance growth stability of a fibrotic cap over the plaque, will reduce the risk of rupture of unstable plaque and inhibit the conversion of stable plaque into unstable plaque.

Methods, systems, and kits for plaque stabilization

View all

Owner:PHARMASONICS

Method of cutting semiconductor wafer and protective sheet used in the cutting method

InactiveUS7060531B2Suppressing progressInhibit progressFilm/foil adhesivesSemiconductor/solid-state device detailsForming faceResist

In a method of cutting a semiconductor wafer in which the semiconductor wafer 6 is cut by plasma etching, a protective sheet 30 on which a metallic layer 30b, a plasma etching rate of which is low, is formed on one face of an insulating sheet 30a is stuck on to a circuit forming face 6a by an adhesive layer 30c, and plasma is exposed onto an opposite side to the circuit forming face 6a from a mask side which is formed by covering regions except for cutting lines 31b with a resist film 31a so as to conduct plasma etching on portions of the cutting lines. Due to the above structure, it is possible to use the metallic layer as an etching stop layer for suppressing the progress of etching. Therefore, fluctuation of the progress of etching can be avoided and heat damage caused on the protective sheet can be prevented.

Method of cutting semiconductor wafer and protective sheet used in the cutting method

View all

Owner:PANASONIC CORP

Cadherin-17 as diagnostic marker and therapeutic target for liver cancer

ActiveUS20100092978A1Inhibit expressionInhibit progressSugar derivativesMicrobiological testing/measurementCancer preventionBacteriuria

Compositions and methods for diagnosing, treating and / or preventing cancers characterized by CDH17 overexpression based on the detection of CDH17 or the use of CDH17 as a target for therapeutic intervention or prophylactic intervention are provided. Methods for diagnosing and / or monitoring liver cancers using the expressing of CDH17 involve detecting and / or quantitating the CDH17 protein or encoding nucleic acids (DNA or RNA) in a biological sample such as urine from the subject. Methods for treating liver cancers using CDH17 as a target and of sensitizing cells with aberrant expression of CDH17 have also been developed. The methods include suppression or knockdown of the expression of CDH17 by administering an effective amount of a CDH17 inhibitor.

Cadherin-17 as diagnostic marker and therapeutic target for liver cancer

View all

Owner:THE UNIVERSITY OF HONG KONG

Methods of modulating immune function

ActiveUS20120219559A1Modulate its functionAdjust immune functionBiocidePeptide/protein ingredientsCTLA-4Autoimmune disease

Presented herein are therapeutic agents that modulate one or more immune functions and uses of such therapeutic agents in the prevention, treatment and management of diseases. In one aspect, the therapeutic agents modulate one or more signal transduction pathways induced by the binding of B7-H7 to B7-H7CR, or the binding of B7-H2 to either ICOS, CD28, or CTLA-4. In another aspect, the therapeutic agents modulate the binding of B7-H7 to B7-H7CR, or the binding of B7-H2 to either ICOS, CD28, or CTLA-4. The therapeutic agents can be used in the prevention, treatment and / or management of diseases in which it might be useful to modulate one or more immune functions (e.g., cancer, infectious disease, autoimmune disease, and transplantation rejection). In another aspect, presented herein are methods for identifying receptor-ligand interactions.

View all

Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE

953results about How to "Inhibit progress" patented technology

Popular searches